GAAP EPS loss widened to $(1.22) from $(1.10) year over year in Q2 2025 as R&D expenses rose 47.7% and G&A expenses climbed 48.8% compared to Q2 2024. VAX-31 vaccine program advanced with FDA expanded ...

Federal vaccine policy changes under RFK Jr. have some concerned health insurance will not cover COVID shots. A bill in NY ...